ClinicalTrials.gg
CompletedNCT05140200Updated May 26, 2026Results posted

Study of GSK3511294 in Healthy Chinese Participants

A Phase 1 interventional study of Depemokimab in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Enrollment
10th of 10
20 · median 273
Started
2021
with 3 others
Phase 1
3 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1, and was the 5th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Single dose study
  • Immunogenicity
  • GSK3511294
  • Chinese healthy participants
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant between 18 to 45 years of age.
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and vital signs.
  • Body weight greater than or equal to (>=)50.0 kilograms (kg) for males, >=45.0 kg for females, and (BMI) within the range (19.0-26.0) kg/meter square (m\^2) (inclusive).
  • use by men and/or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Participant is pregnant, breastfeeding, or a woman of
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Participants with allergy/intolerance to a monoclonal antibody or biologic or participants with a previous history of multiple or severe allergic reactions/intolerance
  • Current evidence or recent history of an infective illness
  • A positive pre-study drug/alcohol screen or a history (or suspected history) of alcohol misuse or substance abuse
  • Clinically significant abnormalities
  • Participants with Coronavirus Disease-2019 (COVID-19)
  • With prior/concurrent clinical study experience.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Depemokimab 100mg

    Healthy Chinese participants received a single dose of 100 mg Depemokimab subcutaneously on Day 1.

    Biological: Depemokimab

  • Experimental
    Depemokimab 300mg

    Healthy Chinese participants received a single dose of 300 mg Depemokimab subcutaneously on Day 1.

    Biological: Depemokimab

Interventions

  • BiologicalDepemokimab

    Depemokimab was administered.

    Also known as: GSK3511294

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Infinity). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183

  2. AUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for AUC(0-T). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183

  3. AUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 4). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 4 post-dose correlates to Day 1 plus 28 days, that is, Day 29.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, and 29

  4. AUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 12). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, that is, Day 85.

    Time frame: Pre-dose (Day 1); 2 h, 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, and 85

  5. AUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 26). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  6. Percentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for percentage of AUC(0-Infinity) obtained by extrapolation. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  7. Maximum Observed Plasma Concentration (Cmax) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  8. Time of Occurrence of Cmax (Tmax) Of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. Tmax was determined directly from the plasma concentration-time data. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  9. Time To Last Quantifiable Concentration (Tlast) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  10. Apparent Clearance (CL/F) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for Apparent Clearance. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  11. Apparent Volume of Distribution (Vz/F) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  12. Terminal Elimination Rate Constant (Lambda Z) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for Terminal elimination rate constant. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

  13. Terminal Phase Half-Life (T1/2) of Depemokimab

    Blood samples were collected from participants at indicated time points and analyzed for Terminal phase half-life. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

    Time frame: Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183

Secondary outcomes

  1. Number of Participants With Adverse Events (AE) And Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is considered or defined as an important medical event.

    Time frame: From the start of the study intervention (Day 1) up to Day 211 (End of follow-up)

  2. Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes

    Blood samples were collected for the assessment of hematology parameters including (WBC) count with differential that is, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26

  3. Change From Baseline in Hematology Parameter: Hemoglobin

    Blood samples were collected for the assessment of change from baseline in hematology parameters including Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

  4. Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected for the assessment of change from baseline in hematology parameters including Hematocrit. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

  5. Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

    Blood samples were collected for the assessment of change from baseline in hematology parameters including mean corpuscular volume. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

  6. Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

    Blood samples were collected for the assessment of change from baseline in hematology parameters including mean Corpuscular Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

  7. Change From Baseline in Hematology Parameter: Reticulocytes

    Blood samples were collected for the assessment of change from baseline in hematology parameters including Reticulocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26

  8. Change From Baseline In Hematology Parameter: Erythrocytes

    Change from baseline in hematology parameter including Erythrocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26

  9. Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea

    Blood samples was collected for the assessment of clinical chemistry parameters including Sodium, potassium, calcium, glucose, and urea. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Pre-dose on Day -1), Week 1, 4, 8, 12, 24 and Week 26

  10. Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine

    Blood samples was collected for the assessment of clinical chemistry parameters including direct bilirubin, bilirubin, and creatinine\[MB10.1\]. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

  11. Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)

    Blood samples was collected for the assessment of clinical chemistry parameters including AST, ALT, ALP, and GGT. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

  12. Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein

    Blood samples was collected for the assessment of clinical chemistry parameters including Albumin. and Total Protein. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

  13. Absolute Values of Complement C3 And C4 at Each Timepoint

    Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

  14. Ratio to Baseline at Each Timepoint of Complement C3 And C4

    Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26

  15. Change From Baseline in Systolic and Diastolic Blood Pressure

    Systolic blood pressure (sBP) is a measure of blood pressure while the heart is beating. Diastolic blood pressure (dBP) is a measure of blood pressure while the heart is relaxed. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26

  16. Change From Baseline in Body Temperature

    Body temperature was measured in participants in resting state. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Day 2, 3, 5, Week 1, 2, 4, 8, 12, 18, 24 and 26

  17. Change From Baseline in Pulse Rate

    The vital signs followed in this analysis was pulse rate, expressed as beats per minute (bpm). Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26

  18. Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate

    12-lead ECG were performed in a supine position using an automated ECG machine that calculated the heart rate and measured PR interval, QRS duration, QT interval and corrected QT using Fridericia's Formula (QTc\[MB13.1\]F) intervals. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the aggregate \[MB14.1\]value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26

  19. Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab

    Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. The results were categorized as negative and positive. A participant is considered positive if they have at least one positive post-Baseline ADA result. Number of participants with positive ADAs against depemokimab was reported in this outcome measure.

    Time frame: Day 1 (Pre-dose), Week 4, Week 12, and Week 26

  20. Titres of Binding ADA's to Depemokimab

    Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. Titer was only measured when a positive result was found.

    Time frame: Up to Week 26

07

Results

Posted May 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneDepemokimab 100mgDepemokimab 300mg
Started1010
Completed109
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Infinity). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183
Reported as:
Geometric mean · day*micrograms per millilitres
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab
day*micrograms per millilitresDepemokimab 100mgDepemokimab 300mg
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab1685.946 (1540.9579 to 1844.5771)5224.107 (4713.2900 to 5790.2848)
PrimaryAUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-T). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Day 1 (Pre-dose, 2h, and 8h Post-dose), Day 2, Day 3, Day 5, Day 8, Day 15, Day 29, Day 57, Day 85, Day 127, Day 169, and Day 183
Reported as:
Geometric mean · day*micrograms per millilitres
AUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab
day*micrograms per millilitresDepemokimab 100mgDepemokimab 300mg
AUC From Time 0 (Pre-Dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-T]) of Depemokimab1472.963 (1346.2052 to 1611.6562)4604.879 (4133.2379 to 5130.3394)
PrimaryAUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 4). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 4 post-dose correlates to Day 1 plus 28 days, that is, Day 29.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, and 29
Reported as:
Geometric mean · day*micrograms per millilitres
AUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab
day*micrograms per millilitresDepemokimab 100mgDepemokimab 300mg
AUC From Time 0 (Pre-dose) to Week 4 (AUC[0-Week 4]) of Depemokimab414.467 (367.9103 to 466.9157)1357.843 (1207.8494 to 1526.4621)
PrimaryAUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 12). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, that is, Day 85.

Time frame:
Pre-dose (Day 1); 2 h, 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, and 85
Reported as:
Geometric mean · day*micrograms per millilitres
AUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab
day*micrograms per millilitresDepemokimab 100mgDepemokimab 300mg
AUC From Time 0 (Pre-dose) To Week 12 (AUC[0-Week 12]) Of Depemokimab1027.083 (933.7879 to 1129.6990)3255.132 (2902.9404 to 3650.0522)
PrimaryAUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for AUC(0-Week 26). Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · day*micrograms per millilitres
AUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab
day*micrograms per millilitresDepemokimab 100mgDepemokimab 300mg
AUC From Time 0 (Pre-dose) To Week 26 [AUC(0-Week 26)] of Depemokimab1472.912 (1346.2052 to 1611.5454)4605.772 (4134.0654 to 5131.3018)
PrimaryPercentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for percentage of AUC(0-Infinity) obtained by extrapolation. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · Percentage of AUCex
Percentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab
Percentage of AUCexDepemokimab 100mgDepemokimab 300mg
Percentage Of AUC(0-Infinity) Obtained by Extrapolation (%AUCex) of Depemokimab12.381 (10.7508 to 14.2591)11.611 (9.9214 to 13.5888)
PrimaryMaximum Observed Plasma Concentration (Cmax) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · micrograms per milliliters (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Depemokimab
micrograms per milliliters (mcg/mL)Depemokimab 100mgDepemokimab 300mg
Maximum Observed Plasma Concentration (Cmax) of Depemokimab16.82 (14.782 to 19.144)55.04 (48.183 to 62.867)
PrimaryTime of Occurrence of Cmax (Tmax) Of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters were calculated by standard non compartmental analysis. Tmax was determined directly from the plasma concentration-time data. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Median · Days
Time of Occurrence of Cmax (Tmax) Of Depemokimab
DaysDepemokimab 100mgDepemokimab 300mg
Time of Occurrence of Cmax (Tmax) Of Depemokimab13.960 (3.98 to 27.95)13.980 (4.00 to 27.98)
PrimaryTime To Last Quantifiable Concentration (Tlast) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Median · Days
Time To Last Quantifiable Concentration (Tlast) of Depemokimab
DaysDepemokimab 100mgDepemokimab 300mg
Time To Last Quantifiable Concentration (Tlast) of Depemokimab181.980 (181.97 to 182.19)181.980 (180.96 to 182.06)
PrimaryApparent Clearance (CL/F) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for Apparent Clearance. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · Liters per day
Apparent Clearance (CL/F) of Depemokimab
Liters per dayDepemokimab 100mgDepemokimab 300mg
Apparent Clearance (CL/F) of Depemokimab0.0593 (0.0542 to 0.0649)0.0574 (0.0518 to 0.0636)
PrimaryApparent Volume of Distribution (Vz/F) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · Litres
Apparent Volume of Distribution (Vz/F) of Depemokimab
LitresDepemokimab 100mgDepemokimab 300mg
Apparent Volume of Distribution (Vz/F) of Depemokimab5.033 (4.5599 to 5.5554)4.827 (4.2489 to 5.4830)
PrimaryTerminal Elimination Rate Constant (Lambda Z) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for Terminal elimination rate constant. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · Per Day
Terminal Elimination Rate Constant (Lambda Z) of Depemokimab
Per DayDepemokimab 100mgDepemokimab 300mg
Terminal Elimination Rate Constant (Lambda Z) of Depemokimab0.0118 (0.0111 to 0.0125)0.0119 (0.0112 to 0.0127)
PrimaryTerminal Phase Half-Life (T1/2) of Depemokimab

Blood samples were collected from participants at indicated time points and analyzed for Terminal phase half-life. Pharmacokinetic parameters were calculated by standard non compartmental analysis. As the first dose of depemokimab was administered on Day 1, Week 26 post-dose correlates to Day 1 plus 182 days, that is, Day 183.

Time frame:
Pre-dose (Day 1); 2 hours (h), 8 h, 24 h, and 48 h post-dose; Days 5, 8, 15, 29, 57, 85, 127, 169, and 183
Reported as:
Geometric mean · Days
Terminal Phase Half-Life (T1/2) of Depemokimab
DaysDepemokimab 100mgDepemokimab 300mg
Terminal Phase Half-Life (T1/2) of Depemokimab58.827 (55.5367 to 62.3132)58.246 (54.7008 to 62.0215)
SecondaryNumber of Participants With Adverse Events (AE) And Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is considered or defined as an important medical event.

Time frame:
From the start of the study intervention (Day 1) up to Day 211 (End of follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) And Serious Adverse Events (SAEs)
ParticipantsDepemokimab 100mgDepemokimab 300mg
Adverse Events1010
Serious Adverse Events00
SecondaryChange From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes

Blood samples were collected for the assessment of hematology parameters including (WBC) count with differential that is, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes
10^9 cells/LDepemokimab 100mgDepemokimab 300mg
Basophils, Day 2-0.000 ± 0.0125-0.007 ± 0.0082
Basophils, Day 3-0.006 ± 0.0126-0.002 ± 0.0123
Basophils, Day 5-0.005 ± 0.0127-0.002 ± 0.0132
Basophils, Week 1-0.007 ± 0.0082-0.009 ± 0.0074
Basophils, Week 2-0.006 ± 0.0107-0.009 ± 0.0099
Basophils, Week 4-0.010 ± 0.0156-0.009 ± 0.0129
Basophils, Week 8-0.001 ± 0.0120-0.011 ± 0.0129
Basophils, Week 12-0.010 ± 0.0105-0.014 ± 0.0133
Basophils, Week 18-0.009 ± 0.0099-0.009 ± 0.0105
Basophils, Week 24-0.005 ± 0.0135-0.016 ± 0.0174
Basophils, Week 26-0.004 ± 0.0135-0.007 ± 0.0100
Eosinophils, Day 2-0.090 ± 0.0720-0.046 ± 0.0401
Eosinophils, Day 3-0.101 ± 0.0824-0.049 ± 0.0463
Eosinophils, Day 5-0.114 ± 0.0875-0.059 ± 0.0404
Eosinophils, Week 1-0.117 ± 0.0858-0.060 ± 0.0429
Eosinophils, Week 2-0.122 ± 0.0889-0.055 ± 0.0414
Eosinophils, Week 4-0.128 ± 0.0986-0.063 ± 0.0499
Eosinophils, Week 8-0.129 ± 0.1092-0.068 ± 0.0432
Eosinophils, Week 12-0.132 ± 0.1017-0.068 ± 0.0435
Eosinophils, Week 18-0.123 ± 0.0943-0.064 ± 0.0522
Eosinophils, Week 24-0.126 ± 0.0982-0.077 ± 0.0480
Eosinophils, Week 26-0.122 ± 0.0919-0.069 ± 0.0506
Lymphocytes, Day 2-0.23 ± 0.337-0.11 ± 0.088
Lymphocytes, Day 3-0.32 ± 0.385-0.16 ± 0.276
Lymphocytes, Day 5-0.14 ± 0.337-0.18 ± 0.204
Lymphocytes, Week 1-0.20 ± 0.327-0.23 ± 0.177
Lymphocytes, Week 2-0.03 ± 0.4400.01 ± 0.191
Lymphocytes, Week 40.12 ± 0.505-0.09 ± 0.260
Lymphocytes, Week 80.16 ± 0.3200.03 ± 0.353
Lymphocytes, Week 12-0.21 ± 0.331-0.04 ± 0.381
Lymphocytes, Week 18-0.11 ± 0.384-0.12 ± 0.291
Lymphocytes, Week 24-0.20 ± 0.422-0.20 ± 0.418
Lymphocytes, Week 26-0.21 ± 0.477-0.18 ± 0.427
Monocytes, Day 2-0.05 ± 0.0850.01 ± 0.057
Monocytes, Day 3-0.06 ± 0.0840.04 ± 0.052
Monocytes, Day 50.01 ± 0.0880.05 ± 0.053
Monocytes, Week 1-0.05 ± 0.0970.04 ± 0.117
Monocytes, Week 2-0.04 ± 0.1260.01 ± 0.074
Monocytes, Week 40.00 ± 0.1150.01 ± 0.057
Monocytes, Week 80.04 ± 0.0520.07 ± 0.125
Monocytes, Week 12-0.06 ± 0.1070.09 ± 0.060
Monocytes, Week 18-0.02 ± 0.0920.08 ± 0.109
Monocytes, Week 24-0.02 ± 0.0790.04 ± 0.053
Monocytes, Week 26-0.03 ± 0.1160.07 ± 0.100
Neutrophils, Day 20.12 ± 1.4970.05 ± 0.693
Neutrophils, Day 3-0.45 ± 0.9920.08 ± 0.960
Neutrophils, Day 5-0.15 ± 0.9410.08 ± 1.090
Neutrophils, Week 1-0.52 ± 1.052-0.21 ± 1.179
Neutrophils, Week 20.19 ± 1.819-0.12 ± 0.878
Neutrophils, Week 4-0.42 ± 1.096-0.01 ± 0.679
Neutrophils, Week 8-0.16 ± 1.178-0.09 ± 1.175
Neutrophils, Week 12-0.48 ± 1.2120.19 ± 0.483
Neutrophils, Week 18-0.39 ± 1.1120.79 ± 0.770
Neutrophils, Week 24-0.06 ± 0.9990.33 ± 0.819
Neutrophils, Week 26-0.13 ± 1.5910.77 ± 1.052
Platelets, Day 2-10.8 ± 12.565.7 ± 12.81
Platelets, Day 3-1.9 ± 14.16-0.3 ± 13.75
Platelets, Day 5-6.1 ± 10.181.7 ± 15.90
Platelets, Week 1-21.8 ± 14.17-5.5 ± 11.71
Platelets, Week 2-9.4 ± 19.974.5 ± 15.50
Platelets, Week 4-10.4 ± 15.777.5 ± 19.55
Platelets, Week 8-13.6 ± 23.773.4 ± 23.24
Platelets, Week 12-15.6 ± 23.684.3 ± 47.56
Platelets, Week 18-11.2 ± 20.43-1.7 ± 29.48
Platelets, Week 24-22.7 ± 19.4522.6 ± 18.77
Platelets, Week 26-18.9 ± 22.26-2.7 ± 25.31
Leukocytes, Day 2-0.240 ± 1.5414-0.070 ± 0.7424
Leukocytes, Day 3-0.900 ± 0.9752-0.100 ± 0.9404
Leukocytes, Day 5-0.390 ± 0.8465-0.080 ± 1.1203
Leukocytes, Week 1-0.880 ± 1.2506-0.480 ± 1.1203
Leukocytes, Week 2-0.020 ± 1.7061-0.140 ± 1.0035
Leukocytes, Week 4-0.400 ± 1.4314-0.180 ± 0.7899
Leukocytes, Week 8-0.090 ± 1.0546-0.080 ± 1.4382
Leukocytes, Week 12-0.870 ± 1.30730.111 ± 0.5883
Leukocytes, Week 18-0.640 ± 1.11970.667 ± 0.7778
Leukocytes, Week 24-0.400 ± 1.10250.034 ± 0.8914
Leukocytes, Week 26-0.470 ± 1.44760.048 ± 1.6991
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected for the assessment of change from baseline in hematology parameters including Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Reported as:
Mean · Gram per Liter
Change From Baseline in Hematology Parameter: Hemoglobin
Gram per LiterDepemokimab 100mgDepemokimab 300mg
Day 2-3.5 ± 7.68-2.1 ± 2.81
Day 3-1.0 ± 6.25-5.2 ± 4.85
Day 5-3.6 ± 10.86-6.2 ± 5.63
Week 1-6.4 ± 10.94-7.0 ± 5.64
Week 2-2.5 ± 7.88-7.5 ± 6.35
Week 4-2.5 ± 7.88-5.8 ± 7.19
Week 8-0.7 ± 9.27-8.9 ± 4.79
Week 12-2.2 ± 8.30-8.9 ± 8.77
Week 18-2.3 ± 8.83-4.0 ± 6.12
Week 24-4.3 ± 8.59-5.4 ± 5.66
Week 26-4.3 ± 6.63-2.6 ± 7.49
SecondaryChange From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected for the assessment of change from baseline in hematology parameters including Hematocrit. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Reported as:
Mean · Liter/liter
Change From Baseline in Hematology Parameter: Hematocrit
Liter/literDepemokimab 100mgDepemokimab 300mg
Day 2-0.0112 ± 0.0148-0.0191 ± 0.0105
Day 3-0.0077 ± 0.0195-0.0231 ± 0.0197
Day 5-0.0136 ± 0.0311-0.0170 ± 0.0180
Week 1-0.0189 ± 0.0327-0.0194 ± 0.0170
Week 2-0.0075 ± 0.0202-0.0210 ± 0.0173
Week 4-0.0092 ± 0.0202-0.0174 ± 0.0181
Week 80.0029 ± 0.0248-0.0210 ± 0.0163
Week 12-0.0032 ± 0.0232-0.0241 ± 0.0221
Week 18-0.0093 ± 0.0234-0.0084 ± 0.0161
Week 240.0003 ± 0.0252-0.0149 ± 0.0099
Week 26-0.0021 ± 0.0164-0.0158 ± 0.0169
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

Blood samples were collected for the assessment of change from baseline in hematology parameters including mean corpuscular volume. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Reported as:
Mean · Femtoliters
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)
FemtolitersDepemokimab 100mgDepemokimab 300mg
Day 2-0.75 ± 0.746-0.23 ± 0.403
Day 31.41 ± 1.4570.60 ± 0.400
Day 5-0.22 ± 0.7730.26 ± 0.493
Week 1-0.46 ± 0.7690.09 ± 0.318
Week 2-0.07 ± 0.6070.17 ± 0.760
Week 40.07 ± 1.0020.53 ± 0.898
Week 80.33 ± 1.1240.77 ± 1.087
Week 12-0.27 ± 1.427-0.10 ± 2.062
Week 18-0.13 ± 1.4250.27 ± 1.885
Week 240.50 ± 0.6270.56 ± 1.544
Week 260.37 ± 0.974-0.96 ± 1.726
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

Blood samples were collected for the assessment of change from baseline in hematology parameters including mean Corpuscular Hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Reported as:
Mean · Picograms (pg)
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Picograms (pg)Depemokimab 100mgDepemokimab 300mg
Day 2-0.01 ± 0.1660.81 ± 0.360
Day 30.86 ± 0.4380.72 ± 0.592
Day 50.20 ± 0.462-0.04 ± 0.267
Week 1-0.13 ± 0.206-0.04 ± 0.313
Week 2-0.16 ± 0.2550.04 ± 0.558
Week 40.13 ± 0.4320.18 ± 0.416
Week 8-0.18 ± 0.266-0.09 ± 0.702
Week 12-0.33 ± 0.374-0.21 ± 0.395
Week 180.17 ± 0.241-0.11 ± 0.504
Week 24-0.69 ± 0.2730.07 ± 0.579
Week 26-0.55 ± 0.3500.24 ± 0.754
SecondaryChange From Baseline in Hematology Parameter: Reticulocytes

Blood samples were collected for the assessment of change from baseline in hematology parameters including Reticulocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26
Reported as:
Mean · Percentage
Change From Baseline in Hematology Parameter: Reticulocytes
PercentageDepemokimab 100mgDepemokimab 300mg
Day 2-0.052 ± 0.14710.085 ± 0.0669
Day 30.601 ± 0.64130.162 ± 0.0933
Day 50.083 ± 0.20900.046 ± 0.1254
Week 10.004 ± 0.15930.071 ± 0.1091
Week 2-0.047 ± 0.16360.118 ± 0.1686
Week 40.123 ± 0.42050.134 ± 0.1686
Week 80.107 ± 0.35780.682 ± 0.4978
Week 120.137 ± 0.17620.656 ± 0.2779
Week 180.037 ± 0.21550.312 ± 0.1923
Week 240.126 ± 0.16750.624 ± 0.3206
Week 260.099 ± 0.12000.318 ± 0.2828
SecondaryChange From Baseline In Hematology Parameter: Erythrocytes

Change from baseline in hematology parameter including Erythrocytes. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and Week 26
Reported as:
Mean · 10^12 cells per liter
Change From Baseline In Hematology Parameter: Erythrocytes
10^12 cells per literDepemokimab 100mgDepemokimab 300mg
Day 2-0.083 ± 0.1904-0.197 ± 0.1225
Day 3-0.160 ± 0.2322-0.289 ± 0.2102
Day 5-0.138 ± 0.3643-0.205 ± 0.2059
Week 1-0.182 ± 0.3466-0.221 ± 0.1875
Week 2-0.080 ± 0.2262-0.242 ± 0.2060
Week 4-0.104 ± 0.1979-0.225 ± 0.2154
Week 80.011 ± 0.2986-0.271 ± 0.1777
Week 12-0.019 ± 0.2729-0.258 ± 0.2909
Week 18-0.097 ± 0.2589-0.107 ± 0.2389
Week 24-0.026 ± 0.2611-0.189 ± 0.1619
Week 26-0.043 ± 0.1945-0.123 ± 0.2421
SecondaryChange From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea

Blood samples was collected for the assessment of clinical chemistry parameters including Sodium, potassium, calcium, glucose, and urea. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Pre-dose on Day -1), Week 1, 4, 8, 12, 24 and Week 26
Reported as:
Mean · Millimoles per liter
Change From Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Calcium, Glucose And Urea
Millimoles per literDepemokimab 100mgDepemokimab 300mg
Sodium, Week 11.1 ± 1.100.9 ± 1.73
Sodium, Week 4-0.3 ± 1.570.1 ± 1.91
Sodium, Week 80.3 ± 1.060.9 ± 2.23
Sodium, Week 12-1.1 ± 1.79-0.1 ± 2.09
Sodium, Week 24-1.7 ± 2.500.7 ± 2.29
Sodium, Week 26-0.9 ± 1.600.1 ± 1.83
Potassium, Week 10.045 ± 0.1932-0.106 ± 0.1246
Potassium, Week 4-0.031 ± 0.2265-0.189 ± 0.2365
Potassium, Week 8-0.028 ± 0.3262-0.242 ± 0.1728
Potassium, Week 12-0.042 ± 0.2665-0.427 ± 0.2293
Potassium, Week 24-0.131 ± 0.2347-0.098 ± 0.1161
Potassium, Week 26-0.106 ± 0.2360-0.252 ± 0.1716
Calcium, Week 10.052 ± 0.1105-0.037 ± 0.0295
Calcium, Week 40.010 ± 0.1159-0.002 ± 0.0432
Calcium, Week 80.065 ± 0.1084-0.018 ± 0.1054
Calcium, Week 120.039 ± 0.1034-0.017 ± 0.0901
Calcium, Week 240.073 ± 0.13350.021 ± 0.0326
Calcium, Week 260.018 ± 0.1036-0.111 ± 0.0824
Urea, Week 10.447 ± 1.16780.084 ± 0.8962
Urea, Week 40.083 ± 0.69650.679 ± 0.9138
Urea, Week 80.251 ± 0.85230.164 ± 1.0094
Urea, Week 120.069 ± 0.61410.102 ± 0.6358
Urea, Week 240.215 ± 0.77880.318 ± 0.5073
Urea, Week 260.179 ± 0.99850.067 ± 0.9667
Glucose, Week 10.151 ± 0.2426-0.138 ± 0.3356
Glucose, Week 40.089 ± 0.25520.327 ± 1.2921
Glucose, Week 80.030 ± 0.3929-0.026 ± 0.3219
Glucose, Week 120.151 ± 0.2487-0.132 ± 0.3391
Glucose, Week 24-0.169 ± 0.41330.468 ± 0.3080
Glucose, Week 26-0.271 ± 0.35110.350 ± 0.6094
SecondaryChange From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine

Blood samples was collected for the assessment of clinical chemistry parameters including direct bilirubin, bilirubin, and creatinine\[MB10.1\]. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Reported as:
Mean · Micromoles per Liter
Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, and Creatinine
Micromoles per LiterDepemokimab 100mgDepemokimab 300mg
Direct Bilirubin, Week 1-0.62 ± 1.2620.17 ± 0.996
Direct Bilirubin, Week 4-0.30 ± 1.572-0.28 ± 1.778
Direct Bilirubin, Week 8-0.77 ± 1.4510.74 ± 1.059
Direct Bilirubin, Week 120.12 ± 2.4040.79 ± 0.862
Direct Bilirubin, Week 24-0.12 ± 1.4970.27 ± 1.228
Direct Bilirubin, Week 260.22 ± 2.1400.61 ± 2.781
Bilirubin, Week 1-2.10 ± 3.5440.14 ± 3.622
Bilirubin, Week 4-1.19 ± 5.297-1.57 ± 6.771
Bilirubin, Week 8-1.27 ± 4.2520.99 ± 2.915
Bilirubin, Week 121.03 ± 6.3650.48 ± 2.618
Bilirubin, Week 24-0.38 ± 4.361-0.32 ± 4.346
Bilirubin, Week 261.06 ± 5.719-1.14 ± 8.219
Creatinine, Week 1-0.6 ± 7.46-4.1 ± 4.09
Creatinine, Week 40.7 ± 4.881.6 ± 6.19
Creatinine, Week 82.5 ± 9.912.5 ± 6.72
Creatinine, Week 120.1 ± 7.49-2.1 ± 5.71
Creatinine, Week 240.1 ± 5.63-1.0 ± 7.19
Creatinine, Week 26-1.5 ± 7.35-0.3 ± 6.75
SecondaryChange From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)

Blood samples was collected for the assessment of clinical chemistry parameters including AST, ALT, ALP, and GGT. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Reported as:
Mean · Units Per Liter
Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)
Units Per LiterDepemokimab 100mgDepemokimab 300mg
ALP, Week 1-1.7 ± 4.92-1.9 ± 6.94
ALP, Week 40.7 ± 7.171.3 ± 6.75
ALP, Week 80.9 ± 7.23-2.7 ± 4.06
ALP, Week 121.5 ± 6.88-3.4 ± 6.44
ALP, Week 243.9 ± 9.34-0.9 ± 9.10
ALP, Week 261.2 ± 6.991.6 ± 7.91
ALT, Week 11.0 ± 6.70-3.4 ± 3.89
ALT, Week 4-0.7 ± 4.32-2.8 ± 8.00
ALT, Week 81.9 ± 6.67-0.8 ± 8.80
ALT, Week 123.6 ± 6.70-1.9 ± 9.97
ALT, Week 243.3 ± 9.24-3.1 ± 8.98
ALT, Week 260.6 ± 6.590.9 ± 18.18
AST, Week 11.5 ± 2.01-0.6 ± 5.13
AST, Week 41.6 ± 3.720.6 ± 6.69
AST, Week 81.3 ± 3.56-0.2 ± 2.86
AST, Week 123.1 ± 4.042.1 ± 4.88
AST, Week 242.9 ± 4.150.2 ± 2.91
AST, Week 261.1 ± 3.484.8 ± 7.64
GGT, Week 10.8 ± 2.94-0.5 ± 2.99
GGT, Week 40.1 ± 2.23-0.2 ± 4.24
GGT, Week 85.6 ± 5.974.1 ± 14.50
GGT, Week 124.2 ± 3.19-0.4 ± 5.70
GGT, Week 245.1 ± 7.82-0.1 ± 6.11
GGT, Week 264.5 ± 4.700.1 ± 7.25
SecondaryChange From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein

Blood samples was collected for the assessment of clinical chemistry parameters including Albumin. and Total Protein. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Reported as:
Mean · Grams per Liter
Change From Baseline In Clinical Chemistry Parameter of Albumin and Total Protein
Grams per LiterDepemokimab 100mgDepemokimab 300mg
Albumin, Week 1-1.13 ± 1.973-1.62 ± 1.266
Albumin, Week 4-0.89 ± 2.529-0.83 ± 1.641
Albumin, Week 8-0.03 ± 1.983-0.57 ± 2.434
Albumin, Week 12-0.73 ± 1.800-0.56 ± 1.965
Albumin, Week 24-2.12 ± 2.1980.20 ± 1.356
Albumin, Week 26-1.59 ± 2.366-0.24 ± 1.775
Total Protein, Week 1-2.49 ± 3.504-2.02 ± 2.147
Total Protein, Week 4-3.61 ± 4.100-1.60 ± 2.659
Total Protein, Week 8-2.67 ± 3.492-1.80 ± 3.629
Total Protein, Week 12-2.44 ± 2.274-2.02 ± 3.337
Total Protein, Week 24-3.22 ± 3.858-1.71 ± 2.461
Total Protein, Week 26-2.38 ± 3.379-2.86 ± 2.511
SecondaryAbsolute Values of Complement C3 And C4 at Each Timepoint

Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Reported as:
Geometric mean · Grams per Liter
Absolute Values of Complement C3 And C4 at Each Timepoint
Grams per LiterDepemokimab 100mgDepemokimab 300mg
Complement C3, Baseline0.876 (0.780 to 0.985)0.913 (0.798 to 1.046)
Complement C3, Week 10.836 (0.745 to 0.939)0.899 (0.798 to 1.012)
Complement C3, Week 40.867 (0.788 to 0.954)0.840 (0.741 to 0.952)
Complement C3, Week 80.888 (0.796 to 0.990)0.896 (0.765 to 1.051)
Complement C3, Week 120.852 (0.755 to 0.961)0.888 (0.772 to 1.023)
Complement C3, Week 240.845 (0.754 to 0.948)0.912 (0.782 to 1.064)
Complement C3, Week 260.883 (0.781 to 0.998)0.886 (0.784 to 1.002)
Complement C4, Baseline0.211 (0.175 to 0.254)0.197 (0.175 to 0.223)
Complement C4, Week 10.205 (0.173 to 0.242)0.200 (0.175 to 0.228)
Complement C4, Week 40.202 (0.170 to 0.241)0.183 (0.156 to 0.214)
Complement C4, Week 80.201 (0.172 to 0.234)0.202 (0.174 to 0.235)
Complement C4, Week 120.194 (0.163 to 0.231)0.213 (0.172 to 0.263)
Complement C4, Week 240.205 (0.174 to 0.242)0.200 (0.168 to 0.238)
Complement C4, Week 260.219 (0.184 to 0.261)0.205 (0.178 to 0.235)
SecondaryRatio to Baseline at Each Timepoint of Complement C3 And C4

Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (Day -1), Week 1, 4, 8, 12, 24 and Week 26
Reported as:
Geometric mean · Ratio
Ratio to Baseline at Each Timepoint of Complement C3 And C4
RatioDepemokimab 100mgDepemokimab 300mg
Complement C3, Week 1 Ratio to Baseline0.954 (0.889 to 1.024)0.984 (0.915 to 1.059)
Complement C3, Week 4, Ratio to Baseline0.989 (0.945 to 1.036)0.919 (0.830 to 1.019)
Complement C3, Week 8, Ratio to Baseline1.013 (0.935 to 1.098)0.981 (0.865 to 1.114)
Complement C3, Week 12, Ratio to Baseline0.972 (0.907 to 1.042)1.002 (0.913 to 1.100)
Complement C3, Week 24, Ratio to Baseline0.965 (0.876 to 1.062)1.028 (0.976 to 1.084)
Complement C3, Week 26, Ratio to Baseline1.008 (0.934 to 1.087)0.999 (0.920 to 1.085)
Complement C4, Week 1, Ratio to Baseline0.972 (0.863 to 1.095)1.013 (0.895 to 1.146)
Complement C4, Week 4, Ratio to Baseline0.959 (0.821 to 1.119)0.926 (0.813 to 1.056)
Complement C4, Week 8, Ratio to Baseline0.952 (0.850 to 1.067)1.024 (0.858 to 1.222)
Complement C4, Week 12, Ratio to Baseline0.919 (0.813 to 1.040)1.101 (0.972 to 1.246)
Complement C4, Week 24, Ratio to Baseline0.973 (0.873 to 1.085)1.034 (0.952 to 1.122)
Complement C4, Week 26, Ratio to Baseline1.040 (0.925 to 1.168)1.060 (0.989 to 1.135)
SecondaryChange From Baseline in Systolic and Diastolic Blood Pressure

Systolic blood pressure (sBP) is a measure of blood pressure while the heart is beating. Diastolic blood pressure (dBP) is a measure of blood pressure while the heart is relaxed. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Days 2, 3, 5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic and Diastolic Blood Pressure
Millimeters of mercury (mmHg)Depemokimab 100mgDepemokimab 300mg
sBP, Day 1 (2 hours)-4.48 ± 6.9330.34 ± 6.963
sBP, Day 1 (8 hours)1.22 ± 6.5222.54 ± 6.318
sBP, Day 21.72 ± 6.0861.34 ± 7.115
sBP, Day 31.22 ± 7.6322.64 ± 7.111
sBP, Day 53.52 ± 8.8772.24 ± 7.363
sBP, Week 14.72 ± 7.952-1.36 ± 6.679
sBP, Week 21.92 ± 5.7970.74 ± 3.063
sBP, Week 40.02 ± 6.091-0.06 ± 5.622
sBP, Week 84.92 ± 5.034-0.66 ± 6.173
sBP, Week 12-2.18 ± 7.9160.08 ± 6.943
sBP, Week 18-1.18 ± 10.5320.52 ± 6.905
sBP, Week 24-2.78 ± 5.8494.52 ± 10.418
sBP, Week 26-4.88 ± 8.5272.97 ± 8.819
dBP, Day 1 (2 hours)1.30 ± 7.002-1.99 ± 7.861
dBP, Day 1 (8 hours)1.90 ± 5.0450.11 ± 5.180
dBP, Day 21.40 ± 3.960-2.29 ± 5.842
dBP, Day 31.60 ± 2.823-3.09 ± 6.931
dBP, Day 53.10 ± 6.056-1.89 ± 6.662
dBP, Week 14.90 ± 4.303-3.39 ± 6.107
dBP, Week 25.20 ± 4.454-4.59 ± 4.786
dBP, Week 44.50 ± 4.463-2.59 ± 5.633
dBP, Week 84.20 ± 6.244-2.49 ± 6.243
dBP, Week 123.20 ± 5.759-1.96 ± 6.028
dBP, Week 184.10 ± 4.078-1.07 ± 6.905
dBP, Week 243.50 ± 4.622-1.73 ± 6.803
dBP, Week 262.50 ± 4.6020.93 ± 8.825
SecondaryChange From Baseline in Body Temperature

Body temperature was measured in participants in resting state. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Day 1 (2 hours), Day 1 (8 hours), Day 2, 3, 5, Week 1, 2, 4, 8, 12, 18, 24 and 26
Reported as:
Mean · Degrees Celsius
Change From Baseline in Body Temperature
Degrees CelsiusDepemokimab 100mgDepemokimab 300mg
Day 1, 2 hours0.07 ± 0.2910.19 ± 0.328
Day 1, 8 hours0.21 ± 0.1520.44 ± 0.284
Day 2-0.05 ± 0.2590.12 ± 0.339
Day 3-0.10 ± 0.3530.11 ± 0.247
Day 5-0.05 ± 0.3410.45 ± 0.381
Week 1-0.25 ± 0.3600.16 ± 0.295
Week 20.01 ± 0.3030.20 ± 0.380
Week 4-0.18 ± 0.336-0.09 ± 0.335
Week 8-0.14 ± 0.2120.28 ± 0.286
Week 12-0.05 ± 0.3310.29 ± 0.330
Week 18-0.04 ± 0.3470.11 ± 0.314
Week 240.01 ± 0.2850.11 ± 0.440
Week 260.20 ± 0.3160.37 ± 0.421
SecondaryChange From Baseline in Pulse Rate

The vital signs followed in this analysis was pulse rate, expressed as beats per minute (bpm). Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26
Reported as:
Mean · Beats per minute (BPM)
Change From Baseline in Pulse Rate
Beats per minute (BPM)Depemokimab 100mgDepemokimab 300mg
Pulse Rate, Day 1, 2 hour-5.96 ± 5.5292.13 ± 6.755
Pulse Rate, Day 1, 8 hour-4.16 ± 5.9991.63 ± 5.892
Pulse Rate, Day 27.24 ± 7.6269.53 ± 8.596
Pulse Rate, Day 31.14 ± 9.1954.53 ± 9.833
Pulse Rate, Day 54.74 ± 13.3786.83 ± 8.631
Pulse Rate, Week 10.94 ± 9.3935.73 ± 6.001
Pulse Rate, Week 25.24 ± 9.9658.53 ± 5.714
Pulse Rate, Week 42.24 ± 10.0367.73 ± 10.994
Pulse Rate, Week 81.24 ± 9.3595.13 ± 8.495
Pulse Rate, Week 120.54 ± 12.4796.62 ± 11.918
Pulse Rate, Week 183.04 ± 15.68911.73 ± 12.640
Pulse Rate, Week 24-0.06 ± 13.60314.73 ± 9.943
Pulse Rate, Week 263.74 ± 15.36514.73 ± 11.377
SecondaryChange From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate

12-lead ECG were performed in a supine position using an automated ECG machine that calculated the heart rate and measured PR interval, QRS duration, QT interval and corrected QT using Fridericia's Formula (QTc\[MB13.1\]F) intervals. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the aggregate \[MB14.1\]value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day -1), Day 1 (2 hour), Day 1 (8 hour), Day 2, 3, 5, Week 1, 4, 8, 12, 18, 24 and Week 26
Reported as:
Mean · Milliseconds
Change From Baseline in ECG Parameters: PR Interval, Aggregate, QRS Duration, Aggregate, QT Interval, Aggregate, QTcF Interval, Aggregate
MillisecondsDepemokimab 100mgDepemokimab 300mg
PR Interval, Aggregate, Day 1, 2 hour-0.84 ± 4.344-2.64 ± 12.942
PR Interval, Aggregate, Day 1, 8 hour-2.27 ± 3.900-3.65 ± 11.480
PR Interval, Aggregate, Day 24.53 ± 12.204-0.46 ± 13.476
PR Interval, Aggregate, Day 3-0.20 ± 8.2950.23 ± 9.007
PR Interval, Aggregate, Day 51.33 ± 7.378-3.38 ± 12.322
PR Interval, Aggregate, Week 11.08 ± 8.925-0.92 ± 11.653
PR Interval, Aggregate, Week 24.04 ± 16.7800.07 ± 9.145
PR Interval, Aggregate, Week 45.45 ± 11.7072.43 ± 12.669
PR Interval, Aggregate, Week 83.46 ± 5.7070.83 ± 11.991
PR Interval, Aggregate, Week 122.53 ± 4.195-1.60 ± 15.803
PR Interval, Aggregate, Week 181.78 ± 3.036-1.32 ± 11.759
PR Interval, Aggregate, Week 242.13 ± 3.876-0.36 ± 15.513
PR Interval, Aggregate, Week 264.40 ± 7.092-2.89 ± 11.269
QRS Duration, Aggregate, Day 1, 2 hour-1.63 ± 1.493-0.82 ± 2.483
QRS Duration, Aggregate, Day 1, 8 hour-0.48 ± 1.954-1.26 ± 1.973
QRS Duration, Aggregate, Day 20.39 ± 2.0230.00 ± 2.253
QRS Duration, Aggregate, Day 31.89 ± 2.8210.41 ± 1.902
QRS Duration, Aggregate, Day 5-0.36 ± 2.627-0.34 ± 3.247
QRS Duration, Aggregate, Week 10.03 ± 1.737-2.27 ± 2.295
QRS Duration, Aggregate, Week 20.26 ± 2.196-0.93 ± 1.937
QRS Duration, Aggregate, Week 40.15 ± 3.106-0.59 ± 1.954
QRS Duration, Aggregate, Week 81.19 ± 2.745-0.80 ± 2.106
QRS Duration, Aggregate, Week 120.93 ± 3.296-0.81 ± 2.597
QRS Duration, Aggregate, Week 181.40 ± 3.3510.02 ± 3.145
QRS Duration, Aggregate, Week 240.46 ± 1.795-2.14 ± 2.546
QRS Duration, Aggregate, Week 26-0.41 ± 3.316-4.07 ± 2.887
QT Interval, Aggregate, Day 1, 2 hour-5.21 ± 5.651-8.39 ± 17.499
QT Interval, Aggregate, Day 1, 8 hour-1.39 ± 8.188-6.92 ± 16.608
QT Interval, Aggregate, Day 2-18.21 ± 8.801-21.93 ± 9.133
QT Interval, Aggregate, Day 3-16.94 ± 14.136-34.99 ± 18.932
QT Interval, Aggregate, Day 5-20.66 ± 16.160-19.39 ± 15.006
QT Interval, Aggregate, Week 1-4.01 ± 12.293-8.60 ± 16.612
QT Interval, Aggregate, Week 2-15.61 ± 17.242-17.66 ± 12.158
QT Interval, Aggregate, Week 4-11.01 ± 14.937-11.07 ± 21.302
QT Interval, Aggregate, Week 8-10.34 ± 14.871-11.67 ± 13.038
QT Interval, Aggregate, Week 12-7.13 ± 18.140-12.78 ± 18.728
QT Interval, Aggregate, Week 18-4.47 ± 22.321-19.39 ± 20.395
QT Interval, Aggregate, Week 24-6.01 ± 26.007-23.96 ± 16.773
QT Interval, Aggregate, Week 26-7.27 ± 22.688-33.78 ± 17.359
QTcF Interval, Aggregate, Day 1, 2 hour-12.59 ± 3.511-11.63 ± 16.082
QTcF Interval, Aggregate, Day 1, 8 hour-6.20 ± 6.892-7.97 ± 7.896
QTcF Interval, Aggregate, Day 2-5.97 ± 6.321-9.73 ± 7.506
QTcF Interval, Aggregate, Day 3-10.09 ± 6.675-26.49 ± 9.100
QTcF Interval, Aggregate, Day 5-7.04 ± 8.360-9.57 ± 8.345
QTcF Interval, Aggregate, Week 1-2.82 ± 6.837-3.45 ± 10.648
QTcF Interval, Aggregate, Week 2-4.94 ± 6.690-7.17 ± 10.401
QTcF Interval, Aggregate, Week 4-2.34 ± 5.754-5.07 ± 10.253
QTcF Interval, Aggregate, Week 8-2.91 ± 7.425-4.00 ± 9.108
QTcF Interval, Aggregate, Week 12-1.84 ± 4.347-5.67 ± 10.444
QTcF Interval, Aggregate, Week 184.98 ± 5.990-2.93 ± 10.040
QTcF Interval, Aggregate, Week 240.62 ± 8.127-8.71 ± 6.705
QTcF Interval, Aggregate, Week 26-1.71 ± 6.968-11.20 ± 10.311
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab

Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. The results were categorized as negative and positive. A participant is considered positive if they have at least one positive post-Baseline ADA result. Number of participants with positive ADAs against depemokimab was reported in this outcome measure.

Time frame:
Day 1 (Pre-dose), Week 4, Week 12, and Week 26
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Depemokimab
ParticipantsDepemokimab 100mgDepemokimab 300mg
Day 1, Pre-dose00
Week 400
Week 1200
Week 2600
SecondaryTitres of Binding ADA's to Depemokimab

Serum samples were collected to determine the presence of anti-depemokimab binding antibodies using a validated bioanalytical method. Data is reported by visit. Titer was only measured when a positive result was found.

Time frame:
Up to Week 26

No measurements were reported for this outcome.

Adverse events

Collected over All-cause mortality, Serious Adverse events (SAE) and non-SAEs were collected from the start of the study intervention (Day 1) up to Day 211 (End of follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Depemokimab 100mg0/10 (0%)0/10 (0%)10/10 (100%)
Depemokimab 300mg0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent other events
Showing 10 of 33
Most frequent other events
EventDepemokimab 100mgDepemokimab 300mg
Blood creatine phosphokinase increasedInvestigations8/104/10
Albumin urine presentInvestigations1/105/10
Blood uric acid increasedInvestigations3/104/10
Red blood cells urine positiveInvestigations1/103/10
Protein urine presentInvestigations0/103/10
Urinary casts presentInvestigations0/103/10
Neutrophil count increasedInvestigations2/101/10
Protein total decreasedInvestigations2/101/10
Bilirubin conjugated increasedInvestigations0/102/10
Upper respiratory tract infectionInfections and infestations2/101/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Depemokimab 100mgDepemokimab 300mgTotal
Mean30.0 ± 6.2329.4 ± 6.9229.7 ± 6.41
Sex: Female, Male
Sex: Female, Male(Participants)Depemokimab 100mgDepemokimab 300mgTotal
Female000
Male101020
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Depemokimab 100mgDepemokimab 300mgTotal
Asian - East Asian Heritage101020
08

Study locations

1 site
  • GSK Investigational Site
    Hangzhou, 310006, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · d3l8i7lo48obsd.cloudfront.net

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Dec 2022, 12 months.

Results were first posted in May 2026, 3 years 5 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 1, 2021
StartActual
Dec 10, 2021
Primary completionActual
Dec 23, 2022
CompletionActual
Dec 23, 2022
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05140200
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Dec 10, 2021
Primary completion
Dec 23, 2022
Completion
Dec 23, 2022
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion